Does ACE inhibition limit structural changes in the heart following myocardial infarction?

Area of Science:

• Cardiovascular biology
• Molecular cardiology
• Pathophysiology of myocardial infarction

Background:

• Cardiac remodeling after myocardial infarction (MI) involves complex cellular changes.
• The renin-angiotensin system (RAS) plays a significant role in post-MI cardiac remodeling.
• Understanding the specific roles of RAS components is vital for therapeutic interventions.

Purpose of the Study:

• To elucidate cellular changes in cardiac remodeling post-MI in rats.
• To investigate the role of the renin-angiotensin system (RAS) in this response.
• To determine the optimal therapeutic strategy targeting RAS early after MI.

Main Methods:

• Experimental induction of myocardial infarction in a rat model.
• Pharmacological inhibition of the renin-angiotensin system (RAS).
• Assessment of cardiomyocyte hypertrophy, interstitial cell DNA synthesis, collagen deposition, and vascularization.

Main Results:

• Angiotensin II AT1 receptor blockade inhibited cardiomyocyte hypertrophy, DNA synthesis, and collagen deposition.
• AT2 receptor activation was linked to diminished vascular outgrowth.
• No evidence of intracardiac RAS activation; systemic RAS activation drives fibrosis and hypertrophy.

Conclusions:

• Systemic RAS activation, not intracardiac, mediates post-MI myocyte hypertrophy and fibrosis.
• Selective AT1 antagonists are appropriate early after MI to inhibit detrimental remodeling.
• AT2 antagonists early post-MI can impair vascularization and cardiac function.